IL2 and metastatic malignant neoplasm: Reduced levels of IL-2 have been associated with a lower survival of metastatic cancer patients (Herberman, 1984; Lissoni et al, 1991), and numerous trials have been performed using IL-2 alone or in combination with other forms of immunotherapy and chemotherapy (Grande et al, 2006).